Accès gratuit
Numéro
Med Sci (Paris)
Volume 17, Numéro 12, Décembre 2001
Page(s) 1297 - 1305
Section Articles de Synthèse
DOI https://doi.org/10.1051/medsci/200117121297
Publié en ligne 15 décembre 2001
  1. Consensus development conference. Prophylaxis and treatment of osteoporosis. Am J Med 1991; 90 : 107–10.
  2. Pacifici R. Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis. J Bone Miner Res 1996; 11 : 1043–51.
  3. Oursler MJ, Osdoby P, Pyfferoen J, et al. Avian osteoclasts as estrogen target cells. Proc Natl Acad Sci USA 1991; 88 : 6613–7.
  4. Melton LJ. How many women have osteoporosis now? J Bone Miner Res 1995; 10 : 175–7.
  5. Cooper C, Campion G, Melton LJ. Hip fractures in the elderly : a world-wide projection. Osteoporos Int 1992; 2 : 285–9.
  6. Melton LJ. Differing patterns of osteoporosis across the world. In : Chesnut CH, ed. New dimensions in osteoporosis in the 1990s. Asia Pacific Conference Series n° 125. Hong Kong : Excerpta Medica, 1991 : 13–8.
  7. Schurch MA, Rizzoli R, Mermillod B, et al. A prospective study on socioeconomic aspects on fracture of the proximal femur. J Bone Miner Res 1996; 11 : 1935–42.
  8. Kellie SE, Brody JA. Sex-specific and racespecific hip fractures rates. Am J Publ Health 1990; 80 : 326–8.
  9. Marotelli RA, Berkman LF, Cooney LM, et al. Decline in physical function following hip fracture. J Am Geriatr Soc 1992; 40 : 861–6.
  10. Kanis JA, McCloskey EV. Epidemiology of vertebral osteoporosis. Bone 1992; 13 : S1–10.
  11. Cooper C, Atkinson EJ, O’Fallen WM, et al. Incidence of clinically diagnosed vertebral fractures : a population-based study in Rochester, Minnesota, 1985–1989. J Bone Miner Res 1992; 7 : 221–7.
  12. Melton LJ, Lane AW, Cooper C, et al. Prevalence and incidence of vertebral deformities. Osteoporos Int 1993; 3 : 113–9.
  13. Owen RA, Melton LJ, Johnson KA, et al. Incidence of Colls’ fractures in a north american community. Am J Publ Health 1982; 72 : 605–7.
  14. Cooper C, Melton LJ. Epidemiology of osteoporosis. Trends Endocrinol Metab 1992; 314 : 224–9.
  15. Pocock NA. Genetic determinants of bone mass in adults. J Clin Invest 1987; 80 : 706–10.
  16. Cummings SR, Cauley J, Palermo L, et al. Racial differences in hip axis lengths might explain racial differences in rates of hip fracture. Osteoporos Int 1994; 4 : 226–9.
  17. Johnell O, Gullberg B, Kanis JA, et al. Risk factors for hip fracture in European women : the MEDOS study. J Bone Miner Res 1995; 10 : 1802–15.
  18. Ross PD, Davis JW, Epstein RS, Wasnish RD. Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med 1991; 114 : 914–23.
  19. Wasnich RD, Davis JW, Ross PD. Spine fracture risk is predicted by non-spine fractures. Osteoporos Int 1994; 4 : 1–5.
  20. Delmas PD, Eastell R, Garnero P, et al. The use of biochemical markers of bone turnover in osteoporosis. Osteoporos Int 2000; suppl 6 : S2–17.
  21. Garnero P, Shih WJ, Gineyts E, et al. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994; 79 : 1693–700.
  22. Garnero P, Sornay-Rendu E, Duboeuf F, Delmas P. Biochemical markers of bone turnover predict postmenopausal forearm bone loss over 4 years : the OFELY study. J Bone Miner Res 1999; 14 : 1614–21.
  23. Hans D, Dargent-Molina P, Schott AM, et al. Ultrasonographic heel measurements to predict hip fracture in elderly women : the EPIDOS prospective study. Lancet 1996; 348 : 511–4.
  24. Kanis JA, Melton LJ, Christiansen C, et al. The diagnosis of osteoporosis. J Bone Miner Res 1994; 9 : 1137–41.
  25. Gardsell P, Johnell O, Nilsson BE. The predictive value of bone loss for fragility fractures in women : a longitudinal study over 15 years. Calcif Tissue Int 1991; 49 : 90–4.
  26. Black DM, Cummings SR, Genant HK, et al. Axial and appendicular bone density predict fractures in older women. J Bone Miner Res 1992; 7 : 633–8.
  27. Cummings SR, Black DM, Newitt MC,et al. Bone density at various sites for prediction of hip fractures. Lancet 1993; 341 : 72–5.
  28. Hesley PP, Shepard KA, Jenkins DK, et al. Monitoring estrogen replacement therapy and identifying rapid bone losers with an immunoassay for deoxypyridinoline. Osteoporos Int 1998; 8 : 159–64.
  29. Cauley JA, Seeley DJ, Ensrud K, et al. Estrogen replacement therapy and fractures in older women. Ann Intern Med 1995; 122 : 9–16.
  30. Lufkin EG, Wahner HW, O’Fallon WM, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 1992; 117 : 1–9.
  31. Felson DT, Zhang Y, Nannan MT, et al. The effect of postmenopausal estrogen therapy on bone density in elderly women. N Engl J Med 1993; 329 : 114–6.
  32. Collaborative Group on Hormonal therapy in breast cancer. Breast cancer and hormone replacement therapy : collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 1997; 350 : 1047–59.
  33. Lin JH. Bisphosphonates : a review of their pharmacokinetic properties. Bone 1996; 18 : 75–85.
  34. Luckman SP, Hughes DE, Coxon FP, et al. Nitrogen-containing bisphosphonates inibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998; 13 : 581–9.
  35. Storm T, Thamsborg G, Steiniche T, Genant HK, Sorensen OH. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990; 322 : 1265–71.
  36. Watts NB, Harris ST, Genant HK, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990; 323 : 73–9.
  37. Black DM, Cummings SR, Karpf DB, et al. Randomized trial of effect of alendronate on risk fracture in women with existing vertebral fractures. Lancet 1996; 348 : 1535–41.
  38. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk fracture in women with low bone density but without vertebral fracture. JAMA 1998; 280 : 2077–82.
  39. Pols HAP, Felsenberg D, Hanley DA, et al. Multinational, placebo-controlled, randomised trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Osteoporos Int 1999; 9 : 461–8.
  40. Hosking D, Chilvers CED, Christiansen C, et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. N Engl J Med 1998; 338 : 485–92.
  41. Harris ST, Watts NB, Genant HK et al. Effects of risedronate treatment vertebral and non vertebral fractures in women with postmenopausal osteoporosis. A randomised controlled trial. JAMA 1999; 282 : 1344–52.
  42. Reginster JY, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000; 11 : 83–91.
  43. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001; 344 : 333–40.
  44. Powles TJ, Hickish T, Kanis JA, et al. Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absoptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 1996; 14 : 78–84.
  45. Delmas PD, Bjarnason NH, Mitlak BH, et al. The effects of raloxifene on bone mineral density, serum cholesterol, and uterine endometrium in postmenopausal women. N Engl J Med 1997; 337 : 1641–7.
  46. Johnston CC Jr, Bjarnason NH, Cohen FJ, et al. Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women : three-year data from 2 doubleblind, randomized, placebo-controlled trials. Arch Intern Med 2000; 160 : 3444–50.
  47. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in post-menopausal women with osteoporosis treated with raloxifene. Results from a 3-year randomized clinical trial. JAMA 1999; 282 : 637–45.
  48. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women. JAMA 1999; 281 : 2189–97.
  49. Cauley JA, Norton L, Lippman ME, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene : 4-year results from the more trial. Multiples outcome of raloxifène evolution. Breast Cancer Res Treat 2001; 65 : 125–34.
  50. Chapuy MC, Arlot ME, Delmas PD, et al. Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. Br Med J 1994; 308 : 1081–2.
  51. Meunier PJ, Sebert JL, Reginster JY, et al. Fluoride salt are no better at preventing new vertebral fractures than calcium-vitamin D in post-menopausal osteoporosis : the FAVOS study. Osteoporos Int 1998; 8 : 4–12.
  52. Chesnut CH, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis : the prevent recurrence of osteoporotic fractures study. PROOF study group. Am J Med 2000; 109: 330–1.
  53. van Staa TP, Wegman S, de Vries F, et al. Use of statins and risk of fractures. JAMA 2001; 285 : 1850–5.
  54. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in post-menopausal women with osteoporosis. N Engl J Med 2001; 344 : 1434–41.
  55. Mosekilde L. Sex differences in age-related changes in vertebral body size, density and biochemical competence in normal individuals. Bone 1990; 11 : 67–73.
  56. Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000; 343 : 604–10.

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.